September 12, 2023
Dell Technologies and University of Limerick Join Forces to Advance Predictive and Diagnostic Cancer Research
- Dell Technologies AI platform drives predictive and diagnostic research in oncology at University of Limerick
- Project to help speed up the diagnosis of B-cell lymphoma and provide enhanced treatment for those with the disease
DUBLIN, Ireland – September 12, 2023 —
Dell Technologies (NYSE:DELL) has joined forces with the University of Limerick’s Digital Cancer Research Centre to develop an artificial intelligence (AI) platform and digital twin technology to power predictive and diagnostic research in oncology.
The technology can help clinicians provide more effective cancer care for those with B-cell lymphoma from speeding diagnosis to providing enhanced treatment and improving long-term outcomes for patients in Ireland and worldwide.
Dell created an AI platform for the University that delivers high performance computing power to accelerate oncology and precision medicine research. The platform sits within the Digital Cancer Centre’s multicloud ecosystem. It is powered by Dell’s latest storage arrays and Dell PowerEdge servers optimised for AI to produce cancer patient digital twins for better diagnostics.
With the new AI platform, researchers can:
- Rapidly accelerate biomarker testing for cancer,
- Gain a better understanding of how to treat patients with B-cell lymphoma, and
- Develop personalised therapies based on a person’s tumour characteristics.
By using emerging technologies, researchers at the Digital Pathology Unit at the University of Limerick’s Digital Cancer Research Centre can also better understand the pathogenesis of these malignancies and develop novel therapeutic approaches. The researchers are particularly interested in the possibility that collagen within the tumour ‘microenvironment’ can cause the cancerous cells to spread around the body and to the central nervous system. Having already identified novel ways to block collagen, the research could lead to new treatments to help cure patients before the tumour spreads.
“Through our partnership with the Dell Technologies team, we will be able to advance our knowledge of how cells go wrong during cancer development and find new ways to diagnose and treat cancer patients,” said Paul Murray, professor of molecular pathology at the University of Limerick and scientific director of the Digital Pathology Unit at the Digital Cancer Research Centre. “This is the beginning of a very exciting research project for the team here at the University of Limerick’s Digital Cancer Research Centre, and we’re looking forward to accelerating this project with the digital support and insights from the team at Dell Technologies.”
“The new AI-driven platform developed by Dell Technologies will ultimately help researchers and healthcare professionals deliver precision treatments for patients with B-cell lymphoma by understanding how it develops,” said Catherine Doyle, managing director, Ireland, Dell Technologies. “Through the creation of these digital twins, the University of Limerick and Dell are taking clinical research to a new level. Together, we are harnessing the power of data through new technologies to benefit patients and healthcare professionals globally.”
Details on the University of Limerick’s Digital Cancer Research Centre can be found at https://www.ul.ie/limerick-dcrc.
About Dell Technologies
Dell Technologies (NYSE:DELL) helps organisations and individuals build their digital future and transform how they work, live and play. The company provides customers with the industry’s broadest and most innovative technology and services portfolio for the data era. www.delltechnologies.com
About University of Limerick
University of Limerick is a research-led, independent, internationally focused university with more than 18,500 students and 1,800 staff. It is a young, energetic and enterprising University with a proud record of innovation in education and excellence in research and scholarship.
- Media Relations Media.Relations@Dell.com